S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VECT

VectivBio (VECT) Stock Price, News & Analysis

$16.85
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$16.85
$16.85
50-Day Range
$16.85
$16.85
52-Week Range
$4.25
$16.98
Volume
N/A
Average Volume
N/A
Market Capitalization
$573.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
VECT stock logo

About VectivBio Stock (NASDAQ:VECT)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

VECT Stock Price History

VECT Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Only two sleeps left until February 31!
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Ironwood seals the deal on VectivBio merger
Q2 2023 Ironwood Pharmaceuticals Inc Earnings Call
See More Headlines
Receive VECT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VECT
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+48.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$27.34 million
Book Value
$6.27 per share

Miscellaneous

Free Float
N/A
Market Cap
$573.24 million
Optionable
No Data
Beta
0.11
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Luca Santarelli M.D. (Age 53)
    Founder, CEO & Director
  • Ms. Claudia D'Augusta Ph.D. (Age 53)
    Chief Financial Officer
  • Dr. Christian Meyer M.D. (Age 56)
    Ph.D., Chief Operating Officer
  • Dr. Alain Bernard Ph.D. (Age 66)
    Chief Technology Officer
  • Mr. Patrick Malloy
    Sr. VP of Investor Relations & Strategic Communications
  • Mr. Scott Applebaum (Age 56)
    Chief Legal Officer & Corp. Sec.
  • Mr. Michael Steininger
    Sr. VP & Head of HR
  • Mr. Kevin Harris M.B.A. (Age 52)
    Chief Commercial Officer
  • Dr. Sarah Holland Ph.D. (Age 60)
    Chief Bus. Officer
  • Dr. Omar Khwaja M.D. (Age 53)
    Ph.D., Chief Medical Officer

VECT Stock Analysis - Frequently Asked Questions

Should I buy or sell VectivBio stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VECT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VECT, but not buy additional shares or sell existing shares.
View VECT analyst ratings
or view top-rated stocks.

What is VectivBio's stock price target for 2024?

3 analysts have issued twelve-month price targets for VectivBio's stock. Their VECT share price targets range from $25.00 to $25.00. On average, they anticipate the company's share price to reach $25.00 in the next year. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for VECT
or view top-rated stocks among Wall Street analysts.

How have VECT shares performed in 2024?

VectivBio's stock was trading at $16.85 at the beginning of the year. Since then, VECT stock has increased by 0.0% and is now trading at $16.85.
View the best growth stocks for 2024 here
.

When is VectivBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 17th 2024.
View our VECT earnings forecast
.

What ETF holds VectivBio's stock?

Range Cancer Therapeutics ETF holds 8,512 shares of VECT stock, representing 1.45% of its portfolio.

When did VectivBio IPO?

VectivBio (VECT) raised $128 million in an IPO on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are VectivBio's major shareholders?

VectivBio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Regency Capital Management Inc. DE (0.00%).

How do I buy shares of VectivBio?

Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VECT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners